Literature DB >> 22025606

Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction.

Judith S Hochman1, Harmony R Reynolds, Vladimír Dzavík, Christopher E Buller, Witold Ruzyllo, Zygmunt P Sadowski, Aldo P Maggioni, Antonio C Carvalho, James M Rankin, Harvey D White, Suzanne Goldberg, Sandra A Forman, Daniel B Mark, Gervasio A Lamas.   

Abstract

BACKGROUND: Despite observations suggesting a benefit for late opening of totally occluded infarct-related arteries after myocardial infarction, the Occluded Artery Trial (OAT) demonstrated no reduction in the composite of death, reinfarction, and class IV heart failure over a 2.9-year mean follow-up. Follow-up was extended to determine whether late trends would favor either treatment group. METHODS AND
RESULTS: OAT randomized 2201 stable patients with infarct-related artery total occlusion >24 hours (calendar days 3-28) after myocardial infarction. Patients with severe inducible ischemia, rest angina, class III-IV heart failure, and 3-vessel/left main disease were excluded. We conducted extended follow-up of enrolled patients for an additional 3 years for the primary end point and angina (6-year median survivor follow-up; longest, 9 years; 12 234 patient-years). Rates of the primary end point (hazard ratio, 1.06; 95% confidence interval, 0.88-1.28), fatal and nonfatal myocardial infarction (hazard ratio, 1.25; 95% confidence interval, 0.89-1.75), death, and class IV heart failure were similar for the percutaneous coronary intervention (PCI) and medical therapy alone groups. No interactions between baseline characteristics and treatment group on outcomes were observed. The vast majority of patients at each follow-up visit did not report angina. There was less angina in the PCI group through early in follow-up; by 3 years, the between group difference was consistently <4 patients per 100 treated and not significantly different, although there was a trend toward less angina in the PCI group at 3 and 5 years. The 7-year rate of PCI of the infarct-related artery during follow-up was 11.1% for the PCI group compared with 14.7% for the medical therapy alone group (hazard ratio, 0.79; 95% confidence interval, 0.61-1.01; P=0.06).
CONCLUSIONS: Extended follow-up of the OAT cohort provides robust evidence for no reduction of long-term rates of clinical events after routine PCI in stable patients with a totally occluded infarct-related artery and without severe inducible ischemia in the subacute phase after myocardial infarction.

Entities:  

Mesh:

Year:  2011        PMID: 22025606      PMCID: PMC3235739          DOI: 10.1161/CIRCULATIONAHA.111.041749

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  24 in total

1.  Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial.

Authors:  Vladimír Dzavík; Christopher E Buller; Gervasio A Lamas; James M Rankin; G B John Mancini; Warren J Cantor; Ronald J Carere; John R Ross; Deborah Atchison; Sandra Forman; Boban Thomas; Pawel Buszman; Carlos Vozzi; Anthony Glanz; Eric A Cohen; Peter Meciar; Gerald Devlin; Alice Mascette; George Sopko; Genell L Knatterud; Judith S Hochman
Journal:  Circulation       Date:  2006-11-14       Impact factor: 29.690

2.  Association of myocardial viability on nitrate-augmented technetium-99m hexakis-2-methoxylisobutyl isonitrile myocardial tomography and intermediate-term outcome in patients with prior myocardial infarction and left ventricular dysfunction.

Authors:  Zuo-Xiang He; Min-Fu Yang; Xiu-Jie Liu; Rong-Fang Shi; Run-Lin Gao; Sheng-Shou Hu; Qing-Yu Wu; Yue-Jin Yang; Ji-Lin Chen
Journal:  Am J Cardiol       Date:  2003-09-15       Impact factor: 2.778

3.  Design and methodology of the Occluded Artery Trial (OAT).

Authors:  Judith S Hochman; Gervasio A Lamas; Genell L Knatterud; Christopher E Buller; Vladimir Dzavik; Daniel B Mark; Harmony R Reynolds; Harvey D White
Journal:  Am Heart J       Date:  2005-10       Impact factor: 4.749

4.  Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.

Authors:  Z M Chen; L X Jiang; Y P Chen; J X Xie; H C Pan; R Peto; R Collins; L S Liu
Journal:  Lancet       Date:  2005-11-05       Impact factor: 79.321

5.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

6.  Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: results from long-term follow-up of the Occluded Artery Trial (OAT) cohort.

Authors:  Harvey D White; Harmony R Reynolds; Antonio C Carvalho; Camille A Pearte; Li Liu; C Edwin Martin; Genell L Knatterud; Vladimír Džavík; Mariusz Kruk; Philippe Gabriel Steg; Warren J Cantor; Venu Menon; Gervasio A Lamas; Judith S Hochman
Journal:  Am Heart J       Date:  2012-04       Impact factor: 4.749

7.  Successful coronary revascularization improves prognosis in patients with previous myocardial infarction and evidence of viable myocardium at thallium-201 imaging.

Authors:  A Cuocolo; M Petretta; E Nicolai; L Pace; D Bonaduce; M Salvatore; B Trimarco
Journal:  Eur J Nucl Med       Date:  1998-01

8.  Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization.

Authors:  Joseph B Selvanayagam; Attila Kardos; Jane M Francis; Frank Wiesmann; Steffen E Petersen; David P Taggart; Stefan Neubauer
Journal:  Circulation       Date:  2004-09-07       Impact factor: 29.690

9.  Prognostic value of detection of myocardial viability using low-dose dobutamine echocardiography in infarcted patients.

Authors:  M Anselmi; G Golia; M Cicoira; M Tinto; M T Nitti; R Trappolin; A Rossi; L Zanolla; P Marino; P Zardini
Journal:  Am J Cardiol       Date:  1998-06-18       Impact factor: 2.778

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  12 in total

1.  Effect of late revascularization of a totally occluded coronary artery after myocardial infarction on mortality rates in patients with renal impairment.

Authors:  Ramin S Hastings; Judith S Hochman; Vladimir Dzavik; Gervasio A Lamas; Sandra A Forman; Francois Schiele; Lampros K Michalis; Dimitris Nikas; Joanna Jaroch; Harmony R Reynolds
Journal:  Am J Cardiol       Date:  2012-06-22       Impact factor: 2.778

2.  Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: analysis of the Occluded Artery Trial (OAT).

Authors:  Harmony R Reynolds; Sandra A Forman; Jacqueline E Tamis-Holland; Philippe Gabriel Steg; Daniel B Mark; Camille A Pearte; Antonio C Carvalho; George Sopko; Li Liu; Gervasio A Lamas; Mariusz Kruk; Krystyna Loboz-Grudzien; Witold Ruzyllo; Judith S Hochman
Journal:  Am Heart J       Date:  2012-03       Impact factor: 4.749

Review 3.  Is ischemia the most powerful indicator of myocardial viability?

Authors:  Jamshid Shirani
Journal:  Curr Cardiol Rep       Date:  2013-05       Impact factor: 2.931

4.  Long-term outcomes after a strategy of percutaneous coronary intervention of the infarct-related artery with drug-eluting stents or bare metal stents vs medical therapy alone in the Occluded Artery Trial (OAT).

Authors:  Xavier Freixa; Vladimír Džavík; Sandra A Forman; James M Rankin; Christopher E Buller; Warren J Cantor; Witold Ruzyllo; Harmony R Reynolds; Gervasio A Lamas; Judith S Hochman
Journal:  Am Heart J       Date:  2012-06       Impact factor: 4.749

5.  Heart failure in post-MI patients with persistent IRA occlusion: prevalence, risk factors, and the long-term effect of PCI in the Occluded Artery Trial (OAT).

Authors:  Rahul R Jhaveri; Harmony R Reynolds; Stuart D Katz; Raban Jeger; Elzbieta Zinka; Sandra A Forman; Gervasio A Lamas; Judith S Hochman
Journal:  J Card Fail       Date:  2012-11       Impact factor: 5.712

6.  Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: results from long-term follow-up of the Occluded Artery Trial (OAT) cohort.

Authors:  Harvey D White; Harmony R Reynolds; Antonio C Carvalho; Camille A Pearte; Li Liu; C Edwin Martin; Genell L Knatterud; Vladimír Džavík; Mariusz Kruk; Philippe Gabriel Steg; Warren J Cantor; Venu Menon; Gervasio A Lamas; Judith S Hochman
Journal:  Am Heart J       Date:  2012-04       Impact factor: 4.749

Review 7.  Myocardial viability in coronary artery chronic total occlusion.

Authors:  Huseng Vefali; Yugandhar Manda; Jamshid Shirani
Journal:  Curr Cardiol Rep       Date:  2015-01       Impact factor: 2.931

Review 8.  Recent advances in the diagnosis and treatment of acute myocardial infarction.

Authors:  Koushik Reddy; Asma Khaliq; Robert J Henning
Journal:  World J Cardiol       Date:  2015-05-26

9.  Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction.

Authors:  Christopher Adlbrecht; Kurt Huber; Harmony R Reynolds; Antonio C Carvalho; Vladimír Džavík; Philippe Gabriel Steg; Li Liu; Paolo Marino; Camille A Pearte; James M Rankin; Harvey D White; Gervasio A Lamas; Judith S Hochman
Journal:  Int J Cardiol       Date:  2014-03-28       Impact factor: 4.164

10.  Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients.

Authors:  Giuseppe Maiolino; Luigi Pedon; Maurizio Cesari; Anna Chiara Frigo; Robert L Wolfert; Marlena Barisa; Leopoldo Pagliani; Giacomo Rossitto; Teresa Maria Seccia; Mario Zanchetta; Gian Paolo Rossi
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.